Jefferies Restarts Coverage of Complete Genomics with 'Buy' Rating | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment bank Jefferies today restarted coverage of Complete Genomics with a 'Buy' rating and $20 price target.

Jefferies had recently served as joint book-runner for Complete Genomics' secondary offering, which raised net proceeds of $73.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.